

# Microvascular Dysfunction Is Associated With a Higher Incidence of Type 2 Diabetes Mellitus A Systematic Review and Meta-Analysis

Citation for published version (APA):

Muris, D. M. J., Houben, A. J. H. M., Schram, M. T., & Stehouwer, C. D. A. (2012). Microvascular Dysfunction Is Associated With a Higher Incidence of Type 2 Diabetes Mellitus A Systematic Review and Meta-Analysis. *Arteriosclerosis Thrombosis and Vascular Biology*, 32(12), 3082-3094. <https://doi.org/10.1161/ATVBAHA.112.300291>

**Document status and date:**

Published: 01/12/2012

**DOI:**

[10.1161/ATVBAHA.112.300291](https://doi.org/10.1161/ATVBAHA.112.300291)

**Document Version:**

Publisher's PDF, also known as Version of record

**Document license:**

Taverne

**Please check the document version of this publication:**

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

**General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

**Take down policy**

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Microvascular Dysfunction Is Associated With a Higher Incidence of Type 2 Diabetes Mellitus

## A Systematic Review and Meta-Analysis

Dennis M.J. Muris, Alfons J.H.M. Houben, Miranda T. Schram, Coen D.A. Stehouwer

**Objective**—Recent data support the hypothesis that microvascular dysfunction may be a potential mechanism in the development of insulin resistance. We examined the association of microvascular dysfunction with incident type 2 diabetes mellitus (T2DM) and impaired glucose metabolism by reviewing the literature and conducting a meta-analysis of longitudinal studies on this topic.

**Methods and Results**—We searched Medline and Embase for articles published up to October 2011. Prospective cohort studies that focused on microvascular measurements in participants free of T2DM at baseline were included. Pooled relative risks were calculated using random effects models. Thirteen studies met the inclusion criteria for this meta-analysis. These studies focused on T2DM or impaired fasting glucose, not on impaired glucose tolerance. The pooled relative risks for incident T2DM (3846 cases) was 1.25 (95% confidence interval, 1.15; 1.36) per 1 SD greater microvascular dysfunction when all estimates of microvascular dysfunction were combined. In analyses of single estimates of microvascular dysfunction, the pooled relative risks for incident T2DM was 1.49 (1.36; 1.64) per 1 SD higher plasma soluble E-selectin levels; 1.21 (1.11; 1.31) per 1 SD higher plasma soluble intercellular adhesion molecule-1 levels; 1.48 (1.03; 2.12) per 1 SD lower response to acetylcholine-mediated peripheral vascular reactivity; 1.18 (1.08; 1.29) per 1 SD lower retinal arteriole-to-venule ratio; and 1.43 (1.33; 1.54) per 1 logarithmically transformed unit higher albumin-to-creatinine ratio. In addition, the pooled relative risks for incident impaired fasting glucose (409 cases) was 1.15 (1.01–1.31) per 1 SD greater retinal venular diameters.

**Conclusion**—These data indicate that various estimates of microvascular dysfunction were associated with incident T2DM and, possibly, impaired fasting glucose, suggesting a role for the microcirculation in the pathogenesis of T2DM. (*Arterioscler Thromb Vasc Biol.* 2012;32:3082–3094.)

**Key Words:** diabetes mellitus ■ meta-analysis ■ microcirculation

Insulin resistance and  $\beta$  cell dysfunction are key features of the pathophysiology of type 2 diabetes mellitus (T2DM), the prevalence of which is rapidly increasing. Central obesity and low physical activity, in turn, are main underlying causes of insulin resistance. We<sup>1</sup> and others<sup>2</sup> have recently advanced the hypothesis that microvascular dysfunction, by impairing the timely access of glucose and insulin to their target tissues, is an additional cause of insulin resistance. In addition, microvascular dysfunction may function as an intermediate step linking central obesity, low physical activity, and chronic low-grade inflammation to insulin resistance<sup>3</sup> (Figure 1).

There is substantial evidence in support of this hypothesis. For example, it has been demonstrated that insulin can redirect blood flow in skeletal muscle from nonnutritive capillaries to nutritive capillaries and thereby increase insulin-mediated glucose uptake without increasing total blood flow.<sup>4</sup> This process, so-called capillary recruitment, is impaired in insulin-resistant individuals.<sup>5,6</sup> In addition, experimental studies have

demonstrated impairments in glucose disposal after blocking insulin-mediated capillary recruitment,<sup>7</sup> suggesting that microvascular dysfunction directly affects insulin-mediated glucose disposal. It is not clear, however, whether there is consistent prospective evidence to support this hypothesis, although, since the early 2000s, a growing number of prospective studies have investigated the association between various estimates of microvascular dysfunction and incident T2DM and impaired fasting glucose (IFG).

In view of these considerations, we conducted a systematic review and meta-analysis of these prospective studies to investigate whether microvascular dysfunction is associated with incident T2DM and IFG in population-based settings

## Materials and Methods

### Search Strategy

We conducted a search in Medline and Embase for studies published from inception (1977) to October 2011. We considered 4 types of

Received on: July 10, 2012; final version accepted on: September 19, 2012.

From the Department of Internal Medicine, Maastricht University Medical Centre (MUMC+), and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands.


The online-only Data Supplement is available with this article at <http://atvb.ahajournals.org/lookup/suppl/doi:10.1161/ATVBAHA.112.300291/-DC1>.

Correspondence to Coen D. A. Stehouwer, Maastricht University Medical Centre, PO Box 5800, 6202 AZ, Maastricht, the Netherlands. E-mail cda.stehouwer@mumc.nl

© 2012 American Heart Association, Inc.

*Arterioscler Thromb Vasc Biol* is available at <http://atvb.ahajournals.org>

DOI: 10.1161/ATVBAHA.112.300291



**Figure 1.** Hypothesis which states that microvascular dysfunction may function as an intermediate step linking central obesity and low physical activity to insulin resistance (and, downstream, type 2 diabetes mellitus) and hypertension (adapted from Jonk<sup>3</sup>). ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blockers; RNF, renin angiotensin factor; TNF- $\alpha$ , tumor necrosis factor.

estimates of microvascular function. First, we included plasma markers of endothelial dysfunction, defined as markers that are synthesized to an important extent by the endothelium (regardless of whether they are also synthesized by other cell types), including soluble E-selectin (sE-selectin), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and von Willebrand factor (vWF).<sup>8</sup> Higher concentrations of these markers are associated with cardiovascular disease<sup>9</sup> and are thought to be derived mainly from microcirculatory endothelium,<sup>10</sup> which makes it plausible that higher concentrations of these markers reflect greater microvascular endothelial dysfunction. Second, we included assessment of skin and muscle microcirculation (by capillaroscopy and laser-Doppler fluxmetry, and plethysmography, respectively), with lower responses reflecting microcirculatory dysfunction. Third, we included retinal diameters, as evaluated by retinal photography. We defined greater venular diameters and both lower arteriolar diameters and lower arteriole-to-venule ratios (AVRs) as markers of microvascular dysfunction, because greater retinal venular diameters are associated with atherosclerosis, inflammation, and cholesterol levels, and both lower AVRs and generalized arteriolar narrowing are associated with incident cardiovascular disease.<sup>11</sup> Finally, we included microalbuminuria, which is thought to reflect a generalized increase in endothelial permeability.<sup>8</sup> Therefore, higher values of urinary albumin excretion (UAE; expressed as albumin-to-creatinine ratio [ACR] or as UAE per time) are thought to reflect greater microvascular endothelial dysfunction.

To identify the studies of interest, we used the following terms: plasma markers of endothelial dysfunction (*sE-selectin*, *sICAM-1*, *sVCAM-1*, *vWF*); peripheral vascular reactivity (*forearm blood flow*, *plethysmography*, *acetylcholine*, *sodium nitroprusside*, *L-NMMA*); skin microvascular endothelium-dependent or -independent reactivity (*iontophoresis*, *intracutaneous injection*, *acetylcholine*, *sodium nitroprusside*, *L-NMMA*); capillary density (*capillary density*, *capillary*

*recruitment*, *capillaroscopy*, *capillaries*); retinal diameters (*retinal vessels*, *arteriovenous ratio*, *AVR*, *venular diameter*, *arteriolar diameter*, *retinal arteriolar diameter*); and microalbuminuria (*microalbuminuria*, *macroalbuminuria*, *albuminuria*, *ACR*, *UAE*). These search strategies were combined with the terms (*risk of*) *diabetes*, *glucose tolerance*, *cohort*, *follow-up*, *longitudinal*. The search was limited to studies within humans and to studies written in English. Finally, we examined the reference lists of the selected papers to find other relevant articles.

## Selection Criteria and Data Extraction

Three authors (D.M.J.M., A.J.H.M.H., and M.T.S.) independently selected articles. Prospective cohort studies that measured microvascular function in participants free of T2DM at baseline were included. First, titles and abstracts of the retrieved studies were scanned and excluded if they were irrelevant. After title and abstract selection, the full text of the included articles was read to identify whether the studies met the prespecified inclusion criteria. After the selection procedure, the following data were extracted: characteristics of the study population, number of participants without T2DM at baseline, incident cases of T2DM or IFG, mean follow-up, definition of T2DM or IFG, the crude and adjusted odds ratios (OR), relative risks (RR) or hazard ratios (HR) with 95%CI, confounding variables included in the analyses, and the incidence and cumulative incidence of T2DM and IFG. When these data were missing, the principal investigator of the selected study was contacted for further information. If the investigator could not provide the requested information or did not respond, the available data were used.

## Statistical Analysis

### Incidences and Cumulative Incidences

When incidence data were not presented in the original article, cases per 1000 person-years and cumulative incidences were calculated. We used the following formulas: cases per 1000 person-years =  $(\text{[T2DM or IFG cases/person-years]} \times 1000)$ , person-years =  $(\text{participants} \times \text{follow-up time})$ , and cumulative incidence =  $(\text{[T2DM or IFG cases/controls]} \times 100\%)$ . If the person-years were not specified in the article, T2DM or IFG cases were set at half of the duration of the follow-up.

### Statistical Analysis for the Meta-Analysis

Meta-analysis was performed by use of RevMan5,<sup>12</sup> using the generic inverse variance method with a random effects model. One SD difference of the independent variable in the fully adjusted models was used to estimate the pooled RRs and 95%CI. The pooled effect sizes were estimated by calculating the logarithm of the RR and the standard error. In this analysis, larger studies with smaller standard errors have a greater weight than smaller studies with larger standard errors. A forest plot was made to show the pooled RRs and 95%CI. We assumed that the populations in the different studies share the same underlying distribution of the microvascular markers. Therefore, different SDs of the microvascular markers are likely to be the result of measurements errors, and risk per 1SD can be compared without conversion.<sup>13</sup> Heterogeneity was assessed visually by forest plots, by means of Cochran's Q test, of which the null hypothesis assumes homogeneity,<sup>14</sup> and by I<sup>2</sup> statistics, which indicates the percentage of variability across trials that is explained by heterogeneity rather than chance.<sup>15</sup>

Because of the highly skewed distribution, the continuous variables ACR and UAE were logarithmically transformed, and results on the association of microalbuminuria with incident T2DM are expressed per logarithmically transformed unit higher ACR or UAE. All logarithmic transformations were to the base e.

## Results

### Study Selection and Characteristics

The literature search resulted in 2722 articles (Figure I in the online-only Data Supplement). After title, abstract, and

full text selection, 23 articles were found that investigated the association of plasma markers of endothelial dysfunction (n=11), peripheral vascular reactivity (n=1), retinal diameters (n=5), and microalbuminuria (n=6), respectively, with incident T2DM or IFG. These studies focused on T2DM or IFG, not on impaired glucose tolerance (IGM). We did not find any articles that prospectively investigated the association of skin microvascular endothelium-dependent or -independent reactivity and capillary density or recruitment with incident IGM or T2DM.

Table 1 shows the characteristics of the selected studies. All articles were published in English after 1994. We found 15 prospective population-based cohort studies,<sup>16–30</sup> 3 prospective nested case-control studies,<sup>31–33</sup> and 5 prospective case-cohort studies.<sup>34–38</sup> The studies examined mainly white participants from Europe, the United States, and Australia. As expected, subjects who developed T2DM during follow-up were slightly older and had a higher body mass index (BMI) at baseline. In addition, 10.2% to 70.2% of the subjects had hypertension at baseline and 9.3% to 72.6% of the subjects were current smokers. The follow-up time of the studies ranged from 2.6 to 12 years. The included studies used different measures to diagnose T2DM and IFG, mainly based on the American Diabetes Association (1997 and 2003) and World Health Organization (1985 and 2006) criteria. Most studies compared incident T2DM with a combined sample of non-T2DM and incident IFG. Two studies<sup>20,21</sup> compared incident T2DM and IFG with non-T2DM.

Plasma samples of sE-selectin, sVCAM-1, sICAM-1, and vWF were analyzed by use of ELISAs. Peripheral vascular reactivity was assessed by a dose-response curve to intra-arterial infusion of acetylcholine (7.5, 15, and 30  $\mu\text{g}\cdot\text{mL}^{-1}\cdot\text{min}^{-1}$ ).<sup>25</sup> Retinal diameters were evaluated offline by the use of fundus photos (Retinal Analysis; Optimate, Madison, WI). ACR or UAE were calculated to determine microalbuminuria. Five studies assessed microalbuminuria in a morning fasting spot urine sample,<sup>18,19,23,27,33</sup> whereas 1 study assessed microalbuminuria by use of two 24-hour urine collections.<sup>16</sup>

### Microvascular Dysfunction and Risk of T2DM

Eleven studies<sup>17,22,26,28,31,32,34–38</sup> investigated the association of microvascular dysfunction as measured by plasma markers of endothelial dysfunction and incident T2DM. Table 1 in the online-only Data Supplement shows a higher incidence of T2DM at higher levels of sE-selectin, sICAM-1, and vWF at baseline. Only the Western New York Study<sup>37</sup> showed a lower incidence of T2DM at a higher level of sICAM-1 at baseline. Table 2 illustrates the associations of plasma markers of endothelial dysfunction with incident T2DM, comparing the upper with the lower tertile/quartile. Plasma markers of sE-selectin, sICAM-1, sVCAM-1, and vWF were positively and significantly associated with incident T2DM. After adjustment for confounders, including age, sex, race, and body composition, sE-selectin and sICAM-1 remained associated with incident T2DM, with RRs ranging from 1.34 (95%CI, 0.91; 1.99) to 4.61 (2.85; 7.46) and from 1.03 (0.64; 1.67) to 1.84 (1.26; 2.69) respectively.

One study investigated the association of peripheral vascular reactivity with incident T2DM.<sup>25</sup> An attenuated endothelium-dependent vasoreactivity response was significantly associated

with incident T2DM; the association remained present after adjustment for age, sex, BMI, smoking, systolic blood pressure, total cholesterol, fasting glucose, fasting insulin, homeostasis model of assessment-insulin resistance, and C-reactive protein (HR 1.30 [1.01; 1.64]).

Five studies assessed the relationship between retinal diameters and incident T2DM.<sup>20,21,24,29,30</sup> Table 1 in the online-only Data Supplement shows a higher incidence of T2DM with smaller baseline arteriolar diameters and AVR. In contrast, venular diameters were not significantly associated with the incidence of T2DM. Table 2 illustrates that lower AVRs were significantly associated with incident T2DM in all 3 studies,<sup>20,29,30</sup> with RRs ranging from 1.53 (1.03; 2.27) to 1.92 (1.10; 3.36). No significant associations were found between either venular or arteriolar diameters and the development of T2DM, except in the AusDiab Study,<sup>24</sup> which showed a significant association for arteriolar diameters (OR, 2.21 [1.02; 4.80]). All studies adjusted for age, sex, smoking, systolic blood pressure, and fasting plasma glucose levels. The studies additionally adjusted for ethnicity, study center, BMI, waist circumference, physical activity, alcohol consumption, diastolic blood pressure, hypertension, family history of diabetes mellitus, total cholesterol, high density lipoprotein cholesterol, fasting insulin levels, IFG/impaired glucose tolerance, cholesterol-lowering medication, follow-up time, HbA1c, carotid plaque score, retinopathy, and ACR, although not all studies used the same variables in the fully adjusted models (Table 2).

Six studies investigated the association between microalbuminuria with incident T2DM.<sup>16,18,19,23,27,33</sup> The incidence of T2DM was higher at higher levels of UAE and ACR, or in presence of microalbuminuria at baseline (Table 1 in the online-only Data Supplement). In addition, all 6 studies showed that the presence of microalbuminuria was significantly associated with incident T2DM. After adjustment for potential confounders, the associations remained present in 5 studies, with RRs ranging from 1.40 (0.82; 2.39) to 2.36 (1.01; 5.50), although studies adjusted for different variables in the analyses (Table 2).

### Meta-Analysis

With regard to plasma markers, 2 studies<sup>34,36</sup> presented their results in figures and therefore did not report exact RR. Five studies presented their data in units that we could not transform into SDs (either tertiles<sup>28,35,37,38</sup> or quintiles.<sup>31</sup>) The remaining 4 studies<sup>22,26,32,36</sup> were included in the meta-analysis. With regard to peripheral vascular reactivity, only 1 study<sup>25</sup> was available (Figure 2). With regard to retinal diameters, all 5 studies<sup>20,21,24,29,30</sup> were included in the meta-analysis and are presented in Figure 2. For microalbuminuria, 3 studies presented UAE<sup>16</sup> and ACR<sup>18,33</sup> as a continuous variable. These studies are presented in Figure 2.

Figure 2 shows that 1 SD greater microvascular dysfunction was associated with a 25% (15; 36%) higher incidence of T2DM. In addition, 1 SD higher levels of plasma markers of endothelial function were associated with a 21% (5; 39%) higher incidence of T2DM. In analyses of single estimates of microvascular dysfunction (Figure 2), 1 SD higher levels of sE-selectin and sICAM-1 were significantly associated with a 49% (36; 64%) and 21% (11; 31%) higher incidence of T2DM, respectively. sVCAM-1 (2% [–9; 16%]) and vWF



Table 1. Characteristics of Selected Studies

| Study   | Ethnicity  | Hypertension, % |    |                        |      |                |      |      |      | Current Smokers, % |    | No. of Participants Without Diabetes Mellitus at Baseline | Incident Cases of Mean Diabetes Mellitus/IFG, y | Follow-Up  | Definitions of IFG or Diabetes Mellitus                            |    |  |
|---|--|-----------------|----|------------------------|------|----------------|------|------|------|--------------------|----|---|---|------------|--|----|--|
|   |  | Age, y          |    | BMI, kg/m <sup>2</sup> |      | Developed T2DM |      |      |      | Yes                |    |   |   |            |  | No |  |
|   |  | Yes             | No | Yes                    | No   | Yes            | No   | Yes  | No   | Yes                | No |   |   |            |  |    |  |
| Plasma markers of endothelial dysfunction   |  |                 |    |                        |      |                |      |      |      |                    |    |   |   |            |  |    |  |
| The Atherosclerosis Risk in Communities study <sup>*17</sup>  | White (78%) and black (22%)                                    | 54              |    | 26.4                   |      | 30             |      | 25   |      |                    |    | 12330   | 1335  | 7          | ADA guidelines use of antidiabetic medication physicians diagnosis |    |  |
| The Framingham offspring study <sup>*22</sup>   | Primarily white  | 54              |    | 25.3                   |      | 38.6           |      | 18.5 |      |                    |    | 924   | 153   | 7          | ADA guidelines use of antidiabetic medication                      |    |  |
| The British regional heart study <sup>*28</sup>   | White  | 68              | 69 | 29.7                   | 26.6 | NA             |      | 9.3  | 13.3 |                    |    | 3562  | 162   | 7          | WHO guidelines physicians diagnosis                                |    |  |
| The prospective study of pravastatin in the elderly at risk <sup>*26</sup>  | White  | 75              | 75 | 26.5                   | 26.8 | 70.2           | 61.9 | 22.3 | 29.0 |                    |    | 4945  | 292   | 3.2        | ADA guidelines self-reported history                               |    |  |
| The Atherosclerosis Risk in Communities study† <sup>35</sup>  | White (47%) and black (53%)                                    | 54              | 53 | 30.5                   | 26.8 | 40.5           | 23.6 | 19.8 | 21.9 |                    |    | 1153  | 581   | 9          | ADA guidelines use of antidiabetic medication physicians diagnosis |    |  |
| The women's health initiative observational study‡ <sup>32</sup>  | White (51%), blacks(29%), hispanics(12%) and Asian/Pacific(8%) | 64              | 64 | 33                     | 26   | NA             |      | NA   |      |                    |    | 3782  | 1584  | 5.9§       | Use of antidiabetic medication self-reported history               |    |  |
| The nurses health study† <sup>31</sup>  | Primarily white  | 56              | 56 | 30.2                   | 26.2 | NA             |      | 14.0 | 13.4 |                    |    | 1522  | 737   | 10         | ADA guidelines use of antidiabetic medication                      |    |  |
| The Monitoring of Trends and Determinants in Cardiovascular Disease and Cooperative Research in the Region of Augsburg studies‡ <sup>38</sup> | White  | 56              | 52 | 29.7                   | 27.1 | 65.8           | 43.9 | 35.1 | 29.4 |                    |    | 2244  | 532   | 12         | Physicians diagnosis self-reported history                         |    |  |
| The Western New York study† <sup>37</sup>   | Primarily white  | 58              | 60 | 32.2                   | 29.5 | 55.9           | 35.1 | 19.7 | 10.8 |                    |    | 219   | 61  | 5.9        | ADA guidelines   |    |  |
| Longitudinal health study in Pima Indians† <sup>36</sup>  | Prime Indians  | 33              | 32 | 36.3                   | 36.3 | NA             |      | NA   |      |                    |    | 142   | 71  | 4.6/6.8/11 | WHO guidelines   |    |  |
| The Monitoring of Trends and Determinants in Cardiovascular Disease and Cooperative Research in the Region of Augsburg studies‡ <sup>34</sup> | White  | 57              | 52 | 30.3                   | 26.7 | 69.5           | 39.5 | 23.9 | 23.3 |                    |    | 1846  | 436   | 10.5       | Physicians diagnosis Self-reported history                         |    |  |
| Peripheral vascular reactivity  |  |                 |    |                        |      |                |      |      |      |                    |    |   |   |            |  |    |  |
| Peritone, 2008 <sup>*25</sup>   | White#   | 50              | 48 | 27.6                   | 27.5 | 100            | 100  | 14   | 19   |                    |    | 400   | 44  | 4.5        | ADA guidelines use of antidiabetic medication                      |    |  |
| Retinal diameters   |  |                 |    |                        |      |                |      |      |      |                    |    |   |   |            |  |    |  |
| The Rotterdam study <sup>*20</sup>  | White  | 5               |    | 26.2%                  |      | NA             |      | 21.8 |      |                    |    | 2309  | 118/305   | 6.4        | ADA guidelines use of antidiabetic medication physicians diagnosis |    |  |

(Continued)

Downloaded from www.ahajournals.org by guest on September 12, 2012

Table 1. (Continued)

| Study  | Ethnicity                       | Hypertension, % |    |                        |      |                |      |                    |      |   |         | Incident Cases of Mean Diabetes Mellitus/IFG, y | Follow-Up  | Definitions of IFG or Diabetes Mellitus |
|--|---------------------------------|-----------------|----|------------------------|------|----------------|------|--------------------|------|---|---------|---|--|---|
|  |                                 | Age, y          |    | BMI, kg/m <sup>2</sup> |      | Developed T2DM |      | Current Smokers, % |      | No. of Participants Without Diabetes Mellitus at Baseline |         |   |  |   |
|  |                                 | Yes             | No | Yes                    | No   | Yes            | No   | Yes                | No   |   |         |   |  |   |
|  |                                 |                 |    |                        |      |                |      |                    |      |   |         |   |  |   |
| The blue mountains eye study <sup>*21</sup>  | White                           | NA              | NA | NA                     | NA   | NA             | NA   | NA                 | NA   | 2123  | 165/104 | 10  | ADA guidelines physicians diagnosis  |   |
| The AusDiab study <sup>*24</sup>   | White                           | 58              | 56 | 30.2                   | 27.5 | 55.7           | 44.2 | 12.4               | 8.8  | 803   | 108     | 4.98  | WHO guidelines use of antidiabetic medication  |   |
| The Atherosclerosis Risk in Communities study <sup>*29</sup>                                   | White (82.9%) and black (17.1%) | 59              |    | 27.9                   |      | NA             | NA   | 16.6               |      | 7993  | 291     | 3.5\$   | ADA guidelines Use of antidiabetic medication physicians diagnosis                                     |   |
| The beaver dam eye study <sup>*30</sup>  | White                           | 50              |    | 28.7                   |      | NA             | NA   | NA                 |      | 3252  | 249     | 10  | Postload plasma glucose>11.1 mmol/L use of antidiabetic medication or diet therapy physician diagnosis |   |
| Microalbuminuria   |                                 |                 |    |                        |      |                |      |                    |      |   |         |   |  |   |
| The strong heart study <sup>*27</sup>  | Americans Indians**             | 56              |    | 31.5                   | 30.1 | 32.6           | 34.2 | 30.4               | 38.5 | 1079  | 391     | 7.8\$   | ADA guidelines   |   |
| The Data from an Epidemiological Study on the Insulin Resistance Syndrome study <sup>*19</sup> | White                           | 47              |    | 24.0                   | 25.3 | 29.4           | 42.0 | 13.3               | 26.3 | 3842  | 171     | 9   | ADA guidelines use of anti-diabetic medication   |   |
| Wang, 2006 <sup>‡,33</sup>   | Aboriginals                     | 36              | 36 | 26.7                   | 26.2 | NA             | NA   | 72.6               | 66.7 | 234   | 117     | 11  | WHO guidelines   |   |
| The Prevention of Renal and Vascular End Stage Disease Study <sup>*16</sup>                    | White                           | 57              | 49 | 29.6                   | 25.8 | 25.4           | 10.2 | NA                 |      | 5654  | 185     | 4.2   | ADA guidelines use of antidiabetic medication  |   |
| Diabetes mellitus prevention program <sup>*18</sup>  | All races**                     | 50              |    | 33                     |      | NA             | NA   | 7.9                |      | 3188  | 674     | 3.2\$   | ADA guidelinesWHO guidelines   |   |
| Mykkanen, 1994 <sup>*23</sup>  | White                           | 69              |    | 27.4                   |      | 49.7           |      | 10.0               |      | 891   | 92      | 3.5   | WHO guidelines†† physician diagnosis††   |   |

ACR indicates albumin-to-creatinine ratio; UAE, urinary albumin excretion; ADA, American Diabetes Association; WHO, World Health Organization; IFG, impaired fasting glucose; T2DM, type 2 diabetes mellitus; NA, not applicable.

ACR milligrams of albumin per gram of creatinine. ACR:30 to 300 mg/day=microalbuminuria; UAE : milligrams albumin per litre urine. UAE: 20 to 200 mg/L=microalbuminuria; ADA guidelines:incident IFG if fasting glucose values reach 6.1 to 7.0 mmol/L. Incident T2DM if fasting glucose values reach ≥7.0 mmol/L; WHO guidelines:incident IFG if fasting glucose values reach 6.1 to 6.9 mmol/L. Incident T2DM if fasting glucose values reach ≥7.0 mmol/L.

\*Cohort study.

†Case-cohort study.

‡Nested-case-cohort study.

§Follow-up described in median.

||Mean follow-up for control subjects.

¶Mean follow-up for case subjects.

#Hypertension at baseline.

\*\*Prediabetes at baseline.

††Definition of Non-insulin-dependent diabetes mellitus(NIDDM).

**Table 2. Unadjusted and Fully Adjusted Association of Plasma Markers of Endothelial Dysfunction, Peripheral Vascular Reactivity, Retinal Diameters, and Microalbuminuria With T2DM and IFG**

| Study  | Risk Marker                                 | Crude IFG Risk | Crude T2DM Risk                         | Fully Adjusted IFG Risk                | Fully Adjusted T2DM Risk                | Adjustment for Confounders <sup>e</sup>   |
|--|---|----------------|---|--|---|---|
| <b>Plasma markers of endothelial dysfunction</b>   |   |                |   |  |   |   |
| The Atherosclerosis Risk in Communities study <sup>17</sup>  | VWF   | NA             | 1.20, ns <sup>a**</sup>                 | 1.50 ( <i>P</i> <0.001) <sup>b§§</sup> | NA                                      | 0.95, ns <sup>a**</sup> 1.30, ns <sup>†††</sup> 1, 3, 4, 6, 9, 10, 15, 16, 19, 21, 22, 26 |
| The Framingham offspring study <sup>22</sup>   | VWF   | NA             | 1.40 (1.12–1.77) <sup>b†</sup>          | NA                                     | 1.33 (1.03–1.72) <sup>b†</sup>          | 2, 7, 9, 10, 11, 13, 14, 16, 19, 21, 24, 27, 28, 29, 30, 31                               |
| The British regional heart study <sup>28</sup>   | VWF   | NA             | 1.39 (0.94–2.03) <sup>b</sup>           | NA                                     | 1.01 (0.67–1.53) <sup>b</sup>           | 1, 2, 5, 7, 9, 10, 11, 16, 33, 34, 35, 36   |
| The prospective study of pravastatin in elderly at risk <sup>26</sup>  | sICAM-1                                     | NA             | 1.60 (1.14–2.25) <sup>c†</sup>          | NA                                     | 1.84 (1.26–2.69) <sup>c†</sup>          | 1, 2, 6, 13, 14, 19, 21, 22, 27   |
| The Atherosclerosis Risk in Communities study <sup>35</sup>  | sICAM-1                                     | NA             | 1.91 (1.45–2.50) <sup>c</sup>           | NA                                     | 1.50 (1.02–2.23) <sup>c</sup>           | 1, 2, 3, 4, 7, 15, 19, 21, 22, 27   |
| The woman's health initiative observational study <sup>32</sup>  | sE-selectin                                 | NA             | 5.48 (4.33–6.94) <sup>b††</sup>         | NA                                     | 2.89 (2.11–3.96) <sup>b††</sup>         | 1, 3, 4, 6, 9, 10, 11, 16, 29, 37, 38   |
|  | sVCAM-1                                     |                | 2.05 (1.62–2.59) <sup>b††</sup>         |  | 1.05 (0.74–1.50) <sup>b††</sup>         |   |
|  | sICAM-1                                     |                | 3.32 (2.67–4.11) <sup>b††</sup>         |  | 1.85 (1.35–2.52) <sup>b††</sup>         |   |
| The nurse's health study <sup>31</sup>   | sE-selectin                                 | NA             | 7.50 (5.05–11.14) <sup>b††</sup>        | NA                                     | 4.61 (2.85–7.46) <sup>b††</sup>         | 1, 3, 6, 9, 10, 11, 16, 22, 27, 29, 39  |
|  | sVCAM-1                                     |                | 1.54 (1.10–2.15) <sup>b††</sup>         |  | 0.64 (0.41–1.00) <sup>b††</sup>         |   |
|  | sICAM-1                                     |                | 4.29 (2.95–6.23) <sup>b††</sup>         |  | 1.75 (1.05–2.92) <sup>b††</sup>         |   |
| The Monitoring of Trends and Determinants in Cardiovascular Disease and Cooperative Research in the Region of Augsburg studies <sup>38</sup> | sE-selectin                                 | NA             | 3.01 (2.18–4.17) <sup>c**</sup>         | NA                                     | 2.63 (1.79–3.88) <sup>c**</sup>         | 1, 4, 6, 9, 10, 11, 13, 16, 19, 21, 27  |
|  | sVCAM-1                                     |                | 2.16 (1.59–2.93) <sup>c**</sup>         |  | 1.32 (0.89–1.96) <sup>c**</sup>         |   |
|  | VWF   |                | 1.43 (0.85–2.40) <sup>c**</sup>         |  | 0.87 (0.44–1.74) <sup>c**</sup>         |   |
| The Western New York study <sup>37</sup>   | sE-selectin                                 | NA             | 3.39 (1.47–7.83) <sup>b</sup>           | NA                                     | 2.77 (1.13–6.79) <sup>b</sup>           | 1, 2, 3, 6, 10, 11, 16, 22, 40  |
|  | sICAM-1                                     |                | 0.08 (0.42–1.87) <sup>b</sup>           |  | NA                                      |   |
| Longitudinal health study in Pima Indians <sup>36</sup>  | sE-selectin                                 | NA             | 1.12 (0.82–1.55) <sup>d</sup>           | NA                                     | 1.39 (0.91–1.99) <sup>d</sup>           | 1, 7, 22, 23, 41, 42  |
|  | sVCAM-1                                     |                | 0.70, ns <sup>d¶</sup>                  |  | 0.90, ns <sup>d¶</sup>                  |   |
|  | sICAM-1                                     |                | 0.70, ns <sup>d¶</sup>                  |  | 0.80, ns <sup>d¶</sup>                  |   |
|  | VWF   |                | 0.67 (0.45–1.00) <sup>d</sup>           |  | 0.73 (0.46–1.16) <sup>d</sup>           |   |
| The Monitoring of Trends and Determinants in Cardiovascular Disease and Cooperative Research in the Region of Augsburg studies <sup>34</sup> | sE-selectin                                 | NA             | 1.80 ( <i>P</i> <0.001) <sup>c*¶¶</sup> | NA                                     | 1.60 ( <i>P</i> <0.001) <sup>c*¶¶</sup> | 1, 2, 4, 6, 9, 10, 11, 13, 16, 18, 19   |
|  | sICAM-1                                     |                | 1.45 ( <i>P</i> <0.001) <sup>c*¶¶</sup> |  | 1.30 ( <i>P</i> =0.031) <sup>c*¶¶</sup> |   |
| <b>Peripheral vascular reactivity</b>  |   |                |   |  |   |   |
| Petricone, 2008 <sup>35</sup>  | Acetyl-choline simulated forearm blood flow | NA             | 1.47 (1.16–1.85) <sup>c¶</sup>          | NA                                     | 1.30 (1.01–1.64) <sup>c¶¶</sup>         | 1, 2, 6, 10, 13, 18, 22, 23, 24, 27   |

(Continued)

Table 2. (Continued)

| Study   | Risk Marker               | Crude IFG Risk                 | Crude T2DM Risk                | Fully Adjusted IFG Risk        | Fully Adjusted T2DM Risk       | Adjustment for Confounders <sup>e</sup>                      |
|---|---------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--|
| <b>Retinal diameters</b>                                    |                           |                                |                                |                                |                                |  |
| The Rotterdam study <sup>20</sup>                           | arteriole-to-venule ratio | NA                             | NA                             | 1.93 (1.35–2.77) <sup>a</sup>  | 1.80 (1.05–3.08) <sup>a</sup>  | 1, 2, 6, 10, 13, 14, 18, 19, 27, 38, 46                      |
|   | Venular diameter          | NA                             | NA                             | 1.46 (1.02–2.08) <sup>a</sup>  | 1.41 (0.83–2.38) <sup>a</sup>  |  |
|   | Arteriolar diameter       | NA                             | NA                             | 1.17 (0.82–1.66) <sup>a</sup>  | 1.29 (0.73–2.28) <sup>a</sup>  |  |
| The blue mountains eye study <sup>21</sup>                  | Venular diameter          | 1.28 (1.04–1.59) <sup>a*</sup> | 1.26 (1.06–1.50) <sup>a*</sup> | 1.16 (0.91–1.47) <sup>a*</sup> | 1.06 (0.87–1.29) <sup>a*</sup> | 1, 2, 6, 10, 11, 13, 16, 19, 22, 32                          |
|   | Arteriolar diameter       | 0.96 (0.77–1.18) <sup>a*</sup> | 1.06 (0.89–1.26) <sup>a*</sup> | 1.02 (0.80–1.30) <sup>a*</sup> | 1.07 (0.88–1.30) <sup>a*</sup> |  |
| The AusDiab study <sup>24</sup>                             | Venular diameter          | NA                             | 1.11 (0.61–2.01) <sup>a</sup>  | NA                             | 0.82 (0.40–1.69) <sup>a</sup>  | 1, 2, 5, 6, 7, 9, 10, 13, 15, 16, 19, 21, 22, 23, 28, 47, 48 |
|   | Arteriolar diameter       | NA                             | 2.14 (1.13–4.05) <sup>a</sup>  |                                | 2.21 (1.02–4.80) <sup>a</sup>  |  |
|   | AV ratio                  | NA                             | 2.76 (1.67–4.58) <sup>a</sup>  | NA                             | 1.92 (1.10–3.36) <sup>a</sup>  | 1, 2, 3, 4, 5, 6, 8, 9, 10, 11, 15, 16, 18, 19, 21, 22, 23   |
| The Atherosclerosis Risk in Communities study <sup>29</sup> | AV ratio                  | NA                             | 1.71 (1.17–2.51) <sup>b</sup>  | NA                             | 1.53 (1.03–2.27) <sup>b</sup>  | 1, 2, 9, 10, 11, 13, 14, 18, 19, 22, 41                      |
| The beaver dam eye study <sup>30</sup>                      | Venular diameter          | NA                             | 1.10 (0.71–1.43) <sup>b</sup>  |                                | 1.03 (0.73–1.46) <sup>b</sup>  |  |
|   | Arteriolar diameter       | NA                             | 1.67 (1.14–2.46) <sup>b</sup>  |                                | 1.47 (0.99–2.18) <sup>b</sup>  |  |

(Continued)



Table 2. (Continued)

| Study   | Risk Marker      | Crude IFG Risk | Crude T2DM Risk                | Fully Adjusted IFG Risk | Fully Adjusted T2DM Risk       | Adjustment for Confounders <sup>e</sup>             |
|---|------------------|----------------|--------------------------------|-------------------------|--------------------------------|---|
| <b>Microalbuminuria</b>   |                  |                |                                |                         |                                |   |
| The strong heart study <sup>27</sup>  | ACR              | NA             | NA                             | NA                      | 1.46 (1.08–1.98) <sup>§</sup>  | 1, 2, 6, 7, 9, 10, 16, 43                           |
| The Data from an Epidemiological Study on the Insulin Resistance Syndrome study <sup>19</sup> | UAE              | NA             | 2.28 (1.39–3.73) <sup>c</sup>  | NA                      | 2.12 (1.76–9.54) <sup>c</sup>  | 1, 6, 9, 10, 15, 16, 22, 23, 24, 26, 27, 28, 33, 44 |
| Wang, 2006 <sup>33</sup>  | ACR              | NA             | 2.22 (1.11–4.48) <sup>b</sup>  | NA                      | 2.36 (1.01–5.50) <sup>b</sup>  | 1, 6, 18, 22, 27                                    |
| The Prevention of Renal and Vascular End Stage Disease study <sup>16</sup>                    | Microalbuminuria |                | 2.22 (1.15–4.29) <sup>§</sup>  |                         | 1.90 (0.88–4.06) <sup>§</sup>  |   |
|   | UAE              | NA             | 1.59 (1.42–1.79) <sup>b</sup>  | NA                      | 1.53 (1.25–1.88) <sup>b</sup>  | 1, 2, 7, 13, 14, 16, 17, 19, 21, 22, 23, 27, 31, 32 |
| Diabetes mellitus prevention program <sup>10</sup>  | ACR              | NA             | 1.07 (1.00–1.10) <sup>cl</sup> | NA                      | 0.98 (0.91–1.06) <sup>cl</sup> | 1, 2, 3, 9, 45                                      |
| Mykkanen, 1994 <sup>23</sup>  | ACR              | NA             | 1.76 (1.07–2.90) <sup>§</sup>  | NA                      | 1.40 (0.82–2.39) <sup>§</sup>  | 1, 2  |

NA indicates not applicable, effect on incident IFG not investigated; ns, not significant; sE, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; VWF, von Willebrand factor; IFG, impaired fasting glucose; ACR, albumin-to-creatinine ratio; UAE, urinary albumin excretion; T2DM, type 2 diabetes mellitus.

IFG and T2DM risk were calculated by the comparison of the upper and lower tertile/quartile, unless otherwise indicated. The fully adjusted models were extracted from the articles.

<sup>a</sup>Odds ratio.

<sup>b</sup>Relative risk.

<sup>c</sup>Hazard ratio.

<sup>d</sup>Incidence rate ratio.

<sup>e</sup>1, age; 2, sex; 3, race; 4, study center; 5, education; 6, body mass index; 7, waist circumference; 8, waist-to-hip ratio; 9, physical activity; 10, smoking; 11, alcohol consumption; 13, systolic blood pressure; 14, diastolic blood pressure; 15, hypertension; 16, family history of diabetes mellitus; 17, family history of cardiovascular disease; 18, total cholesterol; 19, HDL cholesterol; 20, LDL cholesterol; 21, triglycerides; 22, fasting glucose; 23, fasting insulin; 24, homeostasis model of assessment-insulin resistance; 25, social class; 26, fibrinogen; 27, CRP; 28, IFG; 29, postmenopausal hormone therapy; 30, use of aspirin; 31, blood pressure therapy; 32, cholesterol lowering medication; 33, history of cardiovascular disease; 34, use of statins; 35, adiponectin; 36, IL-6; 37, time of blood draw; 38, follow-up time; 39, diet score; 40, yr of baseline visit; 41, HbA 1c; 42, 2-h glucose levels; 43, albuminuria; 44, leucocytes; 45, weight loss; 46, carotid plaque score; 47, retinopathy; 49, micro albumin-to-creatinine ratio.

\*Risk IFG and T2DM per 1SD change in risk marker.

†Risk T2DM per 1QR higher level of VWF.

‡Risk T2DM per 1U higher log[sICAM-1].

§Microalbuminuria absent vs present.


||Risk diabetes mellitus with every doubling of ACR.

¶No exact data, risks estimated from the figure.

#Risk diabetes mellitus per 100% lower vasodilatory response to acetylcholine.

\*\*Association in men.

††Association in women.



**Figure 2.** Forest plot showing the relative risk (RR) and 95%CI for each study, and the pooled RR and 95%CI for risk of type 2 diabetes mellitus. sE-selectin indicates soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cell adhesion molecule-1; vWF, von Willebrand factor.

(15% [−9; 44%]) were not significantly associated with incident T2DM. One SD lower vasodilatory response to acetylcholine was associated with a 48% (3; 102%) higher incidence of T2DM. In addition, 1 SD lower AVR was associated with

an 18% (8; 29%) higher incidence of T2DM. Greater venular diameters and 1 SD lower arteriolar diameters were positively, but not significantly, associated with a 6% (−3; 15%) and 8% (−4; 22%) higher incidence of T2DM, respectively. Finally,

1 logarithmically transformed unit higher UAE or ACR was associated with a 43% (33; 54%) higher incidence of T2DM.

### Microvascular Dysfunction and Risk of IFG

Two studies, the Rotterdam Study<sup>20</sup> and the Blue Mountains Eye Study,<sup>21</sup> investigated the relationship between microvascular dysfunction as measured by retinal diameters and incident IFG. These studies did not specify cumulative incidences per tertile/quartile (Table I in the online-only Data Supplement). Table 2 illustrates the associations of retinal diameters with incident IFG, comparing the upper to the lower tertile/quartile. The Rotterdam Study<sup>20</sup> showed a significant association between both larger venular diameters (OR, 1.46 [1.02; 2.08]) and smaller AVR (OR, 1.93 [1.35; 2.77]), and the development of IFG. The Blue Mountains Eye Study<sup>21</sup> showed a positive association between larger venular diameters (OR, 1.16 [0.91; 1.47]) and the development of IFG. Both studies adjusted for age, sex, BMI, smoking, systolic blood pressure, and high density lipoprotein cholesterol. The Rotterdam Study<sup>20</sup> additionally adjusted for diastolic blood pressure, total cholesterol, C-reactive protein, follow-up time, and carotid plaque score. In contrast, the Blue Mountains Eye Study<sup>21</sup> additionally adjusted for alcohol consumption, family history of diabetes mellitus, fasting plasma glucose levels, and cholesterol-lowering medication.

### Meta-Analysis

One SD greater venular diameters were associated with a 15% (1; 31%) higher incidence of IFG (Figure 3). Arteriolar diameter was not associated with incident IFG. The Rotterdam Study<sup>20</sup> also showed that 1SD lower AVR was associated with a 14% (–2; 32%) higher incidence of IFG.


### Discussion

This study represents the first systematic overview regarding microvascular dysfunction as a risk factor for incident T2DM and IFG. This review had 2 main findings. First, several markers of microvascular dysfunction, including plasma markers,

peripheral vascular reactivity, AVR, and microalbuminuria were associated with incident T2DM. Second, greater venular diameters were associated with incident IFG. These findings are consistent with the hypothesis that microvascular dysfunction is causally linked with T2DM.

Our meta-analysis confirms that microvascular dysfunction was associated with a 10% to 49% higher incidence of T2DM and an 8% to 15% higher incidence of IFG. Several mechanisms, not mutually exclusive, may explain the association between microvascular dysfunction with both T2DM and IFG. First, one underlying mechanism is likely to involve the concept that insulin normally can redirect blood flow in skeletal muscle from nonnutritive capillaries to nutritive capillaries and thereby increase insulin-mediated glucose uptake without increasing total blood flow,<sup>39</sup> and that these processes are impaired in states of microvascular dysfunction, such as obesity, low physical activity, and chronic low-grade inflammation.<sup>3</sup> Notably, specific inhibition of insulin-mediated microvascular effects has been shown to cause a 30% to 40% reduction in glucose disposal.<sup>7</sup> Second, it has been suggested that (pancreatic) microvascular endothelial dysfunction causes apoptosis of  $\beta$  cells in the pancreas.<sup>40</sup> This process decreases insulin secretory capacity and thus may lead to hyperglycemia, which, in addition, can further impair endothelial (microvascular) function, thus leading to a vicious cycle that may play a crucial role in the development of T2DM.<sup>40</sup>

Our analysis demonstrated consistent positive associations across all markers of microvascular endothelial dysfunction used. An important assumption in this reasoning is that these markers are valid indicators of microvascular endothelial dysfunction.<sup>41</sup> The endothelium is a key regulator of permeability, vascular tone, and hemostasis. Thus, endothelial dysfunction can be manifested as increased microvascular permeability and impaired balance between vasodilatation and vasoconstriction, as well as between thrombotic and antithrombotic properties.<sup>8</sup> Likewise, plasma markers of endothelial dysfunction, peripheral vascular reactivity, retinal diameters, and microalbuminuria may reflect different manifestations of these disturbances of the microvascular endothelium. First, E-selectin, ICAM-1, and VCAM-1 are thought to increase endothelial



**Figure 3.** Forest plot showing the relative risks (RR) and 95%CI for each study and the pooled RR and 95%CI for risk of impaired fasting glucose.

permeability to leucocytes, initiated by rolling and endothelial adhesion,<sup>8</sup> and their soluble forms are thought to reflect the concentration of membrane-bound adhesion molecules on the endothelium.<sup>42</sup> In addition, vWF is thought to increase prothrombotic and procoagulant activity.<sup>8</sup> These markers are synthesized by endothelial cells,<sup>8</sup> and the microvascular endothelium, with its large surface area and production capacity (ie, the microvasculature covers 98% of the total vascular surface area),<sup>43</sup> is likely to be the most important determinant of these plasma concentrations.<sup>8</sup> In addition, according to a previously described concept, endothelial dysfunction in large arteries is paralleled by endothelial dysfunction in resistance vessels that contributes to the development of T2DM.<sup>44</sup> For these reasons, it is plausible that higher circulating concentrations of these markers reflect microvascular endothelial dysfunction. Second, acetylcholine is an endothelium-dependent vasodilator because of the release of NO and the production of prostaglandins and endothelium-derived hyperpolarizing factor.<sup>45</sup> Consequently, a lower response in the peripheral microvasculature after stimulation with acetylcholine suggests a defect in the release of NO, endothelium-derived hyperpolarizing factor or prostaglandins, and thus impaired endothelium-dependent vasodilatation. Third, retinal venular dilation and retinal arteriolar narrowing have been associated with endothelial dysfunction.<sup>46,47</sup> Hence, both alterations may represent a directly microvascular phenotype of endothelial dysfunction.<sup>48</sup> In addition, it has been hypothesized that higher intraluminal retinal venular diameters reflect a disrupted endothelial surface layer and thereby increase leukocyte adhesion.<sup>11</sup> This assumption is in line with our meta-analysis, which suggests an association between higher venular diameters and incident IFG. However, because of the use of static fundus photos it is uncertain whether retinal diameters reflect structural or functional microvascular changes. Fourth, microalbuminuria is considered to reflect various aspects of endothelial dysfunction in many vascular beds.<sup>8</sup> This concept is derived from data showing that microalbuminuria is associated with a greater transcapillary escape rate of albumin, that is, with greater microvascular permeability<sup>8</sup> and from data showing that microalbuminuria is strongly associated with risk of cardiovascular disease, that this association cannot be explained by conventional risk factors, and that changes in microalbuminuria are paralleled by changes in cardiovascular risk (reviewed elsewhere).<sup>49</sup>

Strengths of our study include its systematic approach and the evaluation of population-based studies. To identify all studies that assessed the association of microvascular dysfunction with both T2DM and IFG, we extensively searched Medline and Embase. Given the fact that we searched for relatively large population-based studies, it seems unlikely that these studies will have been published and not identified by our search. Therefore, it is likely that we retrieved all published data. All studies included in this systematic review adjusted for multiple confounders, which makes it unlikely that residual confounding may have influenced the results, although we cannot completely exclude this. In contrast, overcorrection may have occurred, as microvascular dysfunction may link central obesity, low physical activity, and chronic, low-grade inflammation to insulin resistance, and be an intermediate step

in the pathophysiologic process.<sup>3</sup> Adjustment for these factors could therefore result in an underestimation of the actual association. In fact, some studies<sup>17,37,38</sup> specifically adjusted for BMI and were able to quantify the exact influence of adjusting for BMI or waist-to-hip ratio (Table II in the online-only Data Supplement). Interestingly, the significant associations among sICAM-1,<sup>37,38</sup> vWF,<sup>17</sup> and sE-selectin<sup>37,38</sup> with incident T2DM decreased after adjustment for BMI or waist-to-hip ratio. Because adjustment for BMI or waist-to-hip ratio may be an over adjustment, we conclude that the reported risks possibly underestimate the true risk for incident T2DM associated with microvascular dysfunction. Another important issue to address is whether the association is different among different subgroups (ie, whether there is effect modification). Three studies included in this systematic review demonstrated significant associations between microvascular dysfunction with incident T2DM in the general population group as well as obese,<sup>31</sup> inflammation,<sup>32</sup> and hypertensive<sup>30</sup> population groups. In addition, at every level of increasing BMI,<sup>31</sup> C-reactive protein,<sup>32</sup> and blood pressure<sup>30</sup> there was a stepwise increase in the association of markers of microvascular dysfunction with incident T2DM. Taken together, these studies suggest that there are significant associations between microvascular dysfunction and incident T2DM in all populations groups, with stronger associations in the obese, inflammation, and hypertensive groups. However, other studies included in this review did not investigate effect modification. Therefore, we cannot definitively conclude that the association is stronger in obese or hypertensive individuals, or at higher levels of inflammation.

The studies included in this review had several limitations. First, because most studies examined mainly white individuals (Table 1), the results of our meta-analysis are not necessarily valid for other ethnicities. For instance, the Longitudinal Health Study<sup>36</sup> examined very obese Pima Indians, who had higher sE-selectin levels as compared with other studies,<sup>31,32,34,37,38</sup> and found no significant associations between plasma markers of endothelial dysfunction and T2DM. The authors concluded that the substantially higher plasma levels might reduce the power to detect an effect of such markers.<sup>36</sup> However, ethnic differences (eg, different population risks) may also explain the variations in T2DM risk. However, the Women's Health Initiative Observational Study<sup>32</sup> showed no major differences between ethnic groups with respect to plasma markers of endothelial dysfunction. In addition, the Monitoring of Trends and Determinants in Cardiovascular Disease and Cooperative Research in the Region of Augsburg studies<sup>38</sup> demonstrated no clear differences between men and women (Table 2 and Table I in the online-only Data Supplement). Second, power problems could explain the lack of significant results in some studies. Mykkanen et al<sup>23</sup> examined 92 incident T2DM cases and demonstrated a positive but nonsignificant relationship between microalbuminuria and incident T2DM, which suggests a lack of power. In contrast, other studies that did demonstrate significant associations,<sup>16,19,27,33</sup> included between 117 and 391 cases of incident T2DM (Table 1). Third, different methods for the assessment of microalbuminuria were used. The Prevention of Renal and Vascular End Stage Disease study<sup>16</sup> assessed microalbuminuria by use of the mean of two



24-hour urine collections (the accepted standard), whereas other studies<sup>18,19,23,27,33</sup> used less precise morning urine samples. Although morning urine samples are a good screening test for albuminuria,<sup>50</sup> its lesser precision may have resulted in less strong associations with wider CI.

Our meta-analysis had some additional limitations. First, the concept that high plasma levels of endothelial dysfunction reflect endothelial dysfunction requires that endothelial cells are the major source of the plasma markers and that higher plasma levels are caused more by increased synthesis than by decreased clearance.<sup>8,41</sup> Indeed, sE-selectin is exclusively synthesized by endothelial cells,<sup>51</sup> which may explain the strong association between sE-selectin and incident T2DM. In addition, in T2DM, higher plasma vWF levels are determined by synthesis rather than clearance.<sup>52</sup> However, sICAM-1, sVCAM-1, and vWF are expressed by several other cell types.<sup>51</sup> Furthermore, except for vWF there is no information on the clearance of these markers. Consequently, the validity of these assumptions remains uncertain.<sup>8,41</sup> Second, we acknowledge the limited availability of prospective studies that could be included in analyses of single estimates of microvascular dysfunction. Because of this low number we could not formally test for heterogeneity,<sup>53</sup> and we could not perform meta-regression analyses. As a consequence, we cannot exclude statistical heterogeneity, although all CIs overlapped (Figures 2 and 3). Third, microvascular function is strongly tissue-dependent.<sup>54</sup> In this systematic overview, we searched for all available prospective population-based studies that focused on any marker of microvascular function. Probably because of the difficulties of microvascular measurements in population-based studies, we only found studies investigating the microcirculation in skin, eye, and kidney. On the one hand, this could limit the generalizability of the data, because the association of microvascular dysfunction and incident T2DM may be tissue-specific (eg, be limited to skeletal muscle microcirculation). On the other hand, the meta-analysis in fact demonstrated that all markers of microvascular dysfunction (skin, eye, as well as kidney) are associated with incident T2DM. This suggests that microvascular function in quite different tissues does have common properties, a notion supported by other data. For example, it has been demonstrated that skeletal muscle microvascular dysfunction was associated with brain microvascular damage among individuals with hypertension.<sup>55</sup>

This systematic review underscores the importance of microvascular dysfunction in the pathogenesis of T2DM. However, this systematic review cannot prove any causal relationship. Therefore, more studies are needed to investigate this. These findings may contribute to more precise assessment of risk of T2DM. In addition, unraveling how microvascular dysfunction is determined and how it leads to T2DM may lead to new treatment targets as well as to a better understanding of why certain existing treatments are associated with decreased risk of developing T2DM (ie, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and physical activity).

In conclusion, we demonstrated that microvascular dysfunction, assessed by use of different methods, was associated

with incident T2DM and even IFG. Our findings are consistent with the hypothesis that microvascular dysfunction is causally linked with T2DM.

## Sources of Funding

This research was supported by Maastricht University Medical Centre (MUMC+).

## Disclosures

None.

## References

- Jonk AM, Houben AJ, Schaper NC, de Leeuw PW, Serné EH, Smulders YM, Stehouwer CD. Angiotensin II enhances insulin-stimulated whole-body glucose disposal but impairs insulin-induced capillary recruitment in healthy volunteers. *J Clin Endocrinol Metab*. 2010;95:3901–3908.
- Liu Z, Liu J, Jahn LA, Fowler DE, Barrett EJ. Infusing lipid raises plasma free fatty acids and induces insulin resistance in muscle microvasculature. *J Clin Endocrinol Metab*. 2009;94:3543–3549.
- Jonk AM, Houben AJ, de Jongh RT, Serné EH, Schaper NC, Stehouwer CD. Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension. *Physiology (Bethesda)*. 2007;22:252–260.
- Rattigan S, Clark MG, Barrett EJ. Hemodynamic actions of insulin in rat skeletal muscle: evidence for capillary recruitment. *Diabetes*. 1997;46:1381–1388.
- Czernichow S, Greenfield JR, Galan P, Bastard JP, Charnaux N, Samaras K, Safar ME, Blacher J, Hercberg S, Levy BI. Microvascular dysfunction in healthy insulin-sensitive overweight individuals. *J Hypertens*. 2010;28:325–332.
- Tack CJ, Ong MK, Lutterman JA, Smits P. Insulin-induced vasodilation and endothelial function in obesity/insulin resistance. Effects of troglitazone. *Diabetologia*. 1998;41:569–576.
- Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. *Am J Physiol Endocrinol Metab*. 2003;285:E123–E129.
- Stehouwer CD. Is measurement of endothelial dysfunction clinically useful? *Eur J Clin Invest*. 1999;29:459–461.
- de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. *Arterioscler Thromb Vasc Biol*. 2006;26:1086–1093.
- To SS, Newman PM, Hyland VJ, Robinson BG, Schrieber L. Regulation of adhesion molecule expression by human synovial microvascular endothelial cells in vitro. *Arthritis Rheum*. 1996;39:467–477.
- Ikram MK, de Jong FJ, Vingerling JR, Witteman JC, Hofman A, Breteler MM, de Jong PT. Are retinal arteriolar or venular diameters associated with markers for cardiovascular disorders? The Rotterdam Study. *Invest Ophthalmol Vis Sci*. 2004;45:2129–2134.
- The Cochrane Collaboration. *Review Manager (RevMan) [Computer program]. Version 5.0*. Copenhagen, Denmark: The Nordic Cochrane Centre; 2008.
- Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. *Circulation*. 2007;115:459–467.
- Egger M, Smith GD, Altman DG. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Deeks JJ, Altman DG, Bradburn MJ, eds. *Systematic reviews in health care. Meta-analysis in context*. 2001.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557–560.
- Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT; PREVEND Study Group. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. *Diabetes Care*. 2005;28:2525–2530.
- Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, Heiss G. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. *Diabetes Care*. 1999;22:767–772.

18. Friedman AN, Friedman A, Marrero D, Ma Y, Ackermann R, Narayan KM, Barrett-Connor E, Watson K, Knowler WC, Horton ES; Diabetes Prevention Program Research Group. Value of urinary albumin-to-creatinine ratio as a predictor of type 2 diabetes in pre-diabetic individuals. *Diabetes Care*. 2008;31:2344–2348.
19. Halimi JM, Bonnet F, Lange C, Balkau B, Tichet J, Marre M; DESIR Study Group. Urinary albumin excretion is a risk factor for diabetes mellitus in men, independently of initial metabolic profile and development of insulin resistance. The DESIR Study. *J Hypertens*. 2008;26:2198–2206.
20. Ikram MK, Janssen JA, Roos AM, Rietveld I, Witteman JC, Breteler MM, Hofman A, van Duijn CM, de Jong PT. Retinal vessel diameters and risk of impaired fasting glucose or diabetes: the Rotterdam study. *Diabetes*. 2006;55:506–510.
21. Kifley A, Wang JJ, Cugati S, Wong TY, Mitchell P. Retinal vascular caliber and the long-term risk of diabetes and impaired fasting glucose: the Blue Mountains Eye Study. *Microcirculation*. 2008;15:373–377.
22. Meigs JB, O'donnell CJ, Tofler GH, Benjamin EJ, Fox CS, Lipinska I, Nathan DM, Sullivan LM, D'Agostino RB, Wilson PW. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. *Diabetes*. 2006;55:530–537.
23. Mykkanen L, Haffner SM, Kuusisto J, Pyörälä K, Laakso M. Microalbuminuria precedes the development of NIDDM. *Diabetes*. 1994;43:552–557.
24. Nguyen TT, Wang JJ, Islam FM, Mitchell P, Tapp RJ, Zimmet PZ, Simpson R, Shaw J, Wong TY. Retinal arteriolar narrowing predicts incidence of diabetes: the Australian Diabetes, Obesity and Lifestyle (AusDiab) Study. *Diabetes*. 2008;57:536–539.
25. Perticone F, Maio R, Sciacqua A, Andreozzi F, Iemima G, Perticone M, Zoccali C, Sesti G. Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. *Diabetes*. 2008;57:167–171.
26. Sattar N, Murray HM, Welsh P, et al; Prospective Study of Pravastatin in Elderly at Risk Trial Study Group. Are elevated circulating intercellular adhesion molecule 1 levels more strongly predictive of diabetes than vascular risk? Outcome of a prospective study in the elderly. *Diabetologia*. 2009;52:235–239.
27. Wang H, Shara NM, Calhoun D, Umans JG, Lee ET, Howard BV. Incidence rates and predictors of diabetes in those with prediabetes: the Strong Heart Study. *Diabetes Metab Res Rev*. 2010;26:378–385.
28. Wannamethee SG, Sattar N, Rumley A, Whincup PH, Lennon L, Lowe GD. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men. *Diabetes Care*. 2008;31:995–1000.
29. Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ, Klein BE, Hubbard LD, Duncan BB; ARIC Investigators. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. *JAMA*. 2002;287:2528–2533.
30. Wong TY, Shankar A, Klein R, Klein BE, Hubbard LD. Retinal arteriolar narrowing, hypertension, and subsequent risk of diabetes mellitus. *Arch Intern Med*. 2005;165:1060–1065.
31. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. *JAMA*. 2004;291:1978–1986.
32. Song Y, Manson JE, Tinker L, Rifai N, Cook NR, Hu FB, Hotamisligil GS, Ridker PM, Rodriguez BL, Margolis KL, Oberman A, Liu S. Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women. *Diabetes*. 2007;56:1898–1904.
33. Wang Z, Hoy WE. Albuminuria as a marker of the risk of developing type 2 diabetes in non-diabetic Aboriginal Australians. *Int J Epidemiol*. 2006;35:1331–1335.
34. Herder C, Baumert J, Zierer A, Roden M, Meisinger C, Karakas M, Chambless L, Rathmann W, Peters A, Koenig W, Thorand B. Immunological and cardiometabolic risk factors in the prediction of type 2 diabetes and coronary events: MONICA/KORA Augsburg case-cohort study. *PLoS ONE*. 2011;6:e19852.
35. Hoogeveen RC, Ballantyne CM, Bang H, Heiss G, Duncan BB, Folsom AR, Pankow JS. Circulating oxidized low-density lipoprotein and intercellular adhesion molecule-1 and risk of type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. *Diabetologia*. 2007;50:36–42.
36. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. *Diabetes Care*. 2003;26:1745–1751.
37. Stranges S, Rafalson LB, Dmochowski J, Rejman K, Tracy RP, Trevisan M, Donahue RP. Additional contribution of emerging risk factors to the prediction of the risk of type 2 diabetes: evidence from the Western New York Study. *Obesity (Silver Spring)*. 2008;16:1370–1376.
38. Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Döring A, Löwel H, Koenig W; MONICA/KORA Study Group. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. *Arterioscler Thromb Vasc Biol*. 2006;26:398–405.
39. Clark MG, Wallis MG, Barrett EJ, Vincent MA, Richards SM, Clerk LH, Rattigan S. Blood flow and muscle metabolism: a focus on insulin action. *Am J Physiol Endocrinol Metab*. 2003;284:E241–E258.
40. Tal MG. Type 2 diabetes: Microvascular ischemia of pancreatic islets? *Med Hypotheses*. 2009;73:357–358.
41. De Jager J, Kooy A, Leher P, Bets D, Wulffelé MG, Teerlink T, Scheffer PG, Schalkwijk CG, Donker AJ, Stehouwer CD. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. *J Intern Med*. 2005;257:100–109.
42. Heyl W, Handt S, Reister F, Gehlen J, Mittermayer C, Rath W. The role of soluble adhesion molecules in evaluating endothelial cell activation in preeclampsia. *Am J Obstet Gynecol*. 1999;180(1 Pt 1):68–72.
43. Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. *Circ Res*. 1980;47:301–311.
44. Pinkney JH, Stehouwer CD, Coppock SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. *Diabetes*. 1997;46 Suppl 2:S9–13.
45. Rubanyi GM. Endothelium-derived relaxing and contracting factors. *J Cell Biochem*. 1991;46:27–36.
46. Klein R, Sharrett AR, Klein BE, Chambless LE, Cooper LS, Hubbard LD, Evans G. Are retinal arteriolar abnormalities related to atherosclerosis? The Atherosclerosis Risk in Communities Study. *Arterioscler Thromb Vasc Biol*. 2000;20:1644–1650.
47. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cyclooxygenase-2 and nitric oxide. *Curr Pharm Des*. 2004;10:3331–3348.
48. Liew G, Wang JJ, Mitchell P, Wong TY. Retinal vascular imaging: a new tool in microvascular disease research. *Circ Cardiovasc Imaging*. 2008;1:156–161.
49. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms. *J Am Soc Nephrol*. 2006;17:2106–2111.
50. Houlihan CA, Tsalamandris C, Akdeniz A, Jerums G. Albumin to creatinine ratio: a screening test with limitations. *Am J Kidney Dis*. 2002;39:1183–1189.
51. Price DT, Loscalzo J. Cellular adhesion molecules and atherogenesis. *Am J Med*. 1999;107:85–97.
52. Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CD, Thomsen C, Rasmussen O, Hermansen K, Wollheim CB, Ingerslev J, von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII). *Thromb Haemost*. 1998;80:1002–1007.
53. Schriger DL, Altman DG, Vetter JA, Heafner T, Moher D. Forest plots in reports of systematic reviews: a cross-sectional study reviewing current practice. *Int J Epidemiol*. 2010;39:421–429.
54. Knotzer H, Hasibeder WR. Microcirculatory function monitoring at the bedside—a view from the intensive care. *Physiol Meas*. 2007;28:R65–R86.
55. Greenstein AS, Paranthaman R, Burns A, Jackson A, Malik RA, Baldwin RC, Heagerty AM. Cerebrovascular damage in late-life depression is associated with structural and functional abnormalities of subcutaneous small arteries. *Hypertension*. 2010;56:734–740.